TD Cowen analyst Gary Taylor lowered the firm’s price target on Elevance Health (ELV) to $484 from $589 and keeps a Buy rating on the shares. The firm updated its model and corresponding estimates in conjunction with its Q3 earnings preview.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $478 from $585 at RBC Capital
- Elevance Health cut to Hold at Argus on earnings pressure in 2024-2025
- Elevance Health price target lowered to $520 from $620 at Truist
- Elevance Health downgraded to Hold from Buy at Argus
- Elevance Health price target lowered to $555 from $605 at UBS